According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026.

This key development has removed regulatory obstacles for all parties to advance the previously announced licensing agreement. The conclusion of this agreement marks a new substantive phase in the related cooperation. Passing the HSR antitrust review is a crucial step in strategic collaborations involving intellectual property and market access. This usually means that regulatory authorities have determined the transaction will not materially harm competition in the relevant market. With this regulatory threshold crossed, all parties are expected to accelerate implementation of the detailed terms of the licensing agreement, boosting progress in related R&D or commercialization projects. This dynamic is being closely watched by industry observers.